Ardea's HIV Drug Found Effective in Preclinical Studies
Posted on: Friday, 8 February 2008, 09:00 CST
Ardea Biosciences has presented preclinical data that demonstrated the potent activity of the company's non-nucleoside reverse transcriptase inhibitor family of compounds against the human-immunodeficiency virus, the known causative agent of AIDS, including NNRTI-resistant strains.
The data showed that Ardea's lead NNRTI candidate, RDEA806, is a potent inhibitor of HIV, including the most common efavirenz resistant viruses. Oral dosing with RDEA806 achieved trough levels in humans that average at least 10-fold higher than the serum-adjusted EC50.
Barry Quart, president and CEO of Ardea, said: "This level of exposure over the concentration of drug needed to inhibit replication of the virus by 50% supports the potential for promising antiviral activity of our drug in HIV-infected patients who are naive to antiretroviral therapy."
Source: Datamonitor
Related Articles
- Ardea Biosciences to Present at the Piper Jaffray 19th Annual Health Care Conference
- Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
- Ardea's Oral MEK Inhibitor Shows Favorable Anti-Tumor Activity
- Ardea Biosciences to List on the NASDAQ Capital Market
- Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
- Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
- Ardea Biosciences Says Phase I HIV Drug Trial Success
- Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
- Ardea Biosciences, Inc. Announces Appointment of Patrick M. O'Connor As Senior Vice President of Research and Preclinical Development and Chief Scientific Officer
- PepsiAmericas Buys Ardea Beverage Co.; Functional Beverage Line Provides Portfolio Expansion
 |
 |
User Comments (0)
RSS Feeds